Cancer Drug Resistance: The Why, The How and The What-Next?
Imoh S. Okon*
Center for Molecular and Translational Medicine, Georgia State University, Atlanta, USA
- *Corresponding Author:
- Imoh S. Okon
Center for Molecular and Translational Medicine
Georgia State University, Atlanta, USA
E-mail: [email protected]
Received date: October 02, 2015; Accepted date: October 15, 2015; Published date: October 22, 2015
Citation: Okon IS (2015) Cancer Drug Resistance: The Why, The How and The What-Next? Mol Biol 4:140. doi:10.4172/2168-9547.1000140
Copyright: © 2015 Okon IS. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Astronomic advances in cancer therapy has been achieved in recent years. Specifically, the last 10-20 years has witnessed the advent of target-specific anti-cancer agents that have provided relative but significant benefits. Traditional chemo and radio–therapy approaches, while still in use and necessary in certain cases (instances) lack target specificity which means that off-target, bystander effects to non-cancer cells could be detrimental, and trigger gene mutations that fuel the initiation of “new” malignant cells. Beyond potential alterations to noncancer cells, the import and wider implications of non-targeted cancer therapies are unknown, and may likely impact several cellular signaling events. Therefore, the emergence of tyrosine kinase inhibitors (TKIs) that target specific aberrantly expressed or activated genes has provided an alternative approach that minimizes off-target effects.